Scientists Turn Gut Cells Into Insulin Producers—A New Path for Type 1 Diabetes Treatment

Type 1 diabetes develops when the immune system mistakenly attacks and destroys the beta cells in the pancreas that produce insulin. Once these cells are gone, the body cannot regulate blood sugar on its own. Researchers have long sought ways to replace these lost cells, but finding a reliable, renewable source has proven difficult.

Most approaches have focused on the pancreas itself—either transplanting donated tissue or growing new beta cells from stem cells. Each method faces practical hurdles: donor organs are scarce, and growing cells in the lab is complex and expensive. A new study suggests an unexpected solution: look not at the pancreas, but at the gut.

Researchers discovered that they could reprogram L-cells—a type of endocrine cell found throughout the gastrointestinal tract—into insulin-producing cells by introducing a single protein called Pax4. In living organisms, this reprogramming successfully converted gut L-cells into cells that behaved like pancreatic beta cells.

The converted gut cells displayed the key characteristics of real beta cells: they expressed insulin-related proteins, contained components necessary for sensing blood glucose levels, and could process the hormone proinsulin into mature, functional insulin. In organoid models (miniaturized tissue structures grown in the lab), these cells demonstrated glucose-responsive insulin secretion—meaning they released insulin when exposed to high blood sugar, just as normal beta cells do.

The gastrointestinal tract has two major advantages as a cell source. First, it is enormous compared to the pancreas—the gut epithelium covers a much larger area, meaning more L-cells could potentially be reprogrammed. Second, the gut naturally regenerates itself constantly, replacing its lining every few days. This inherent regenerative capacity suggests that partial reprogramming of gut cells might create a renewable source of insulin-producing cells over time.

These properties make the gut an attractive alternative to pancreatic tissue, which is limited in size and difficult to harvest.

This research demonstrates proof of concept in animal models and laboratory systems—an important milestone, but only a first step. The findings show that gut cell reprogramming is biologically feasible and that the resulting cells function like beta cells in controlled settings.

Many challenges remain before this approach could become a treatment. Researchers will need to determine whether reprogrammed gut cells survive long-term, how to ensure they integrate properly into the body, and whether the immune system—which destroyed the original beta cells in Type 1 diabetes—would attack these new cells. Human trials are still many years away.

Nevertheless, this work opens a new avenue for developing cell-based therapies that could one day offer people with Type 1 diabetes an alternative to current insulin management strategies.

Source: Cells. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.